ArticleCancers2018
Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease.
Article in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients.Molecular oncology · 2026Article
- Decoding Brain Metastasis With Liquid Biopsy: Biomarkers and Technologies in EGFR-Mutant NSCLC.Cancer medicine · 2026Review
- Liquid biopsies for the monitoring of gliomas and brain metastases in adults.Acta neuropathologica · 2025Review
- Harnessing exosomes for targeted drug delivery systems to combat brain cancer.Cancer cell international · 2025Review
- CXCL12-loaded-hydrogel (CLG): A new device for metastatic circulating tumor cells (CTCs) capturing and characterization.Heliyon · 2024Article
- Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives.Signal transduction and targeted therapy · 2024Review
- Advancements in Circulating Tumor Cell Research: Bridging Biology and Clinical Applications.Cancers · 2024Review
- Exploring the Molecular Tumor Microenvironment and Translational Biomarkers in Brain Metastases of Non-Small-Cell Lung Cancer.International journal of molecular sciences · 2024Review
- Unveiling the dynamics of circulating tumor cells in colorectal cancer: from biology to clinical applications.Frontiers in cell and developmental biology · 2024Review
- Oligometastasis: Expansion of Curative Treatments in the Field of Oncology.Medicina (Kaunas, Lithuania) · 2023Review
- Research Progress on Nanomaterials for Tissue Engineering in Oral Diseases.Journal of functional biomaterials · 2023Review
- Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer.NPJ breast cancer · 2023Review
- Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders.Molecules (Basel, Switzerland) · 2023Review
- Isolation, Detection and Analysis of Circulating Tumour Cells: A Nanotechnological Bioscope.Pharmaceutics · 2023Review
- Development and clinical validation of a microfluidic-based platform for CTC enrichment and downstream molecular analysis.Frontiers in oncology · 2023Article
- Circulating tumor cells and extracellular vesicles as liquid biopsy markers in neuro-oncology: prospects and limitations.Neuro-oncology advances · 2022Article
- Differences in actionable genomic alterations between brain metastases and non‑brain metastases in patients with non‑small cell lung cancer.International journal of oncology · 2022Article
- Article
- Tumour invasion and dissemination.Biochemical Society transactions · 2022Review
- Liquid biopsies to occult brain metastasis.Molecular cancer · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Forty percent of non-small cell lung cancer (NSCLC) patients develop brain metastases, resulting in a dismal prognosis. However, patients in an oligo-metastatic brain disease setting seem to have better outcomes. Here, we investigate the possibility of using circulating tumor cells (CTCs) as biomarkers to differentiate oligo-metastatic patients for better risk assessment. Using the CellSearch
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.